IOL Chemicals & Pharmaceuticals IOL Chemicals & Pharmaceuticals delivered strong financial performance in the first quarter of FY27, reporting significant growth across key profitability metrics. The company’s standalone profit before tax (PBT) surged 90.5% year-on-year to ₹86.8 crore, up from ₹45.5 crore in Q1FY26. Net profit after tax followed suit, rising 89.9% to ₹64.5 crore from ₹34.0 crore in the corresponding previous period.

Revenue from operations grew by 37.1% to ₹756.3 crore in Q1FY27, compared to ₹551.7 crore in Q1FY26. This top-line expansion was accompanied by improved operational efficiency, with EBITDA jumping 60.7% to ₹111.7 crore. Consequently, the EBITDA margin expanded by 220 basis points to 14.6% from 12.4% in the prior year quarter. Earnings before interest and taxes (EBIT) also rose sharply by 81.7% to ₹90.4 crore.

Segmental and Geographical Performance

The pharmaceutical segment continued to be the primary revenue driver, generating ₹469.5 crore in Q1FY27, up from ₹374.5 crore in Q1FY26. This represents a 25.4% year-on-year growth for the pharma business. The chemicals segment, net of intersegment transfers, contributed ₹286.8 crore, marking a substantial recovery from ₹244.9 crore in Q1FY26.

Geographically, the company remains heavily reliant on international markets. Exports accounted for 71% of total revenue, while domestic sales constituted the remaining 29%. This export-oriented structure highlights the company’s integration into global supply chains, particularly for active pharmaceutical ingredients (APIs) and specialty chemicals.

What the Numbers Show

A notable divergence exists between revenue growth and cost management in Q1FY27. While revenue grew 37.1%, employee benefits expense increased by only 23.4% (from ₹57.7 crore to ₹71.2 crore). Similarly, finance costs declined slightly to ₹3.6 crore from ₹4.2 crore in the prior year period. This suggests improved operating leverage, where fixed costs are being spread over a larger revenue base, directly contributing to the margin expansion observed in EBITDA and PAT percentages.

Balance Sheet and Cash Flow Position

As of March 2026, the company maintained a healthy balance sheet with total equity standing at ₹1,798.4 crore. Total borrowings under current liabilities were ₹132.0 crore, while non-current financial liabilities remained negligible at zero. Cash and cash equivalents at the end of FY26 stood at ₹65.3 crore, down from ₹78.0 crore at the end of FY25, reflecting ongoing capital investments and working capital requirements.

Operating cash flows remained robust, with net cash from operating activities totaling ₹214.4 crore in FY26, compared to ₹178.7 crore in FY25. This strong cash generation supports the company’s expansion plans, including the recently acquired 101-acre land parcel near Chandigarh-Bathinda Highway for future manufacturing capacity.

Strategic Outlook

The company continues to diversify beyond its core Ibuprofen business. The non-Ibuprofen share in the pharmaceuticals segment has grown from 18% to 37% over the past six years. Key products driving this diversification include Paracetamol, Metformin, Clopidogrel, Fenofibrate, and Pantoprazole. With 14 DMFs filed with the USFDA and 21 CEPs with EDQM, IOL Chemicals is positioned to expand its footprint in regulated markets.

The investor presentation, submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was signed by Abhay Raj Singh, Sr. Vice President & Company Secretary, on August 12, 2026.

IOL Chemicals and Pharmaceuticals Limited has issued a communication to shareholders who have not registered their email addresses, providing a web-link to access the Notice for its 39th Annual General Meeting (AGM) and the Integrated Annual Report for FY26. This disclosure, made pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensures that all members can access critical corporate governance documents despite the company’s shift to electronic-only distribution for registered users. The AGM is scheduled for September 2, 2026, and will address key resolutions including the adoption of financial statements which reported a standalone revenue of ₹2,319.06 crore and a profit after tax (PAT) of ₹137.72 crore for FY26.

Communication to Unregistered Shareholders

The company clarified that physical copies of the Annual Report are not being dispatched. Instead, shareholders without registered email IDs with the Company, Registrar and Transfer Agent (RTA), or Depository Participants (DPs) must access the documents digitally. The notice, dated August 7, 2026, and signed by Sr. Vice President & Company Secretary Abhay Raj Singh, directs these members to scan a QR code or visit the company’s investor relations website at https://www.iolcp.com/investors/annual-reports .

The documents are also available on the websites of BSE Limited, National Stock Exchange of India Limited, and Central Depository Services Limited (CDSL) at https://www.evotingindia.com . This move aligns with regulatory efforts to promote paperless corporate communications while maintaining transparency for all stakeholders.

AGM Details and Shareholder Action Required

The 39th AGM will be held on Wednesday, September 2, 2026, at 11:30 a.m. (IST) via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). Members holding shares in physical mode or those with outdated email records are urged to update their details immediately to facilitate smooth participation and future dividend processing.

Shareholders can contact the RTA, Alankit Assignments Limited, at +91-11-4254 1234 / 4254 1958 for assistance. The Register of Members will remain closed from August 27, 2026, to September 2, 2026.

Voting and Compliance

Remote e-voting will be facilitated by CDSL, with the voting window opening on August 30, 2026, at 9:00 a.m. and closing on September 1, 2026, at 5:00 p.m. Only shareholders on the record date of August 26, 2026, are eligible to vote. The facility for appointing proxies is not available for this meeting, though institutional shareholders may appoint authorized representatives under Section 113 of the Companies Act, 2013. Mr. Vinay Kohli of M/s K.K. Kapoor & Associates has been appointed as the scrutinizer for the e-voting process.